Ranibizumab for age-related macular degeneration

Expert Opinion on Biological Therapy

Volumn 12, Issue 3, 2012, Pages 371-381

  Dhoot, Dilsher S ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN A;

BINDING KINETICS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOPHTHALMITIS; HUMAN; IC 50; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TREATMENT OUTCOME; UNITED STATES; UVEITIS; VITREOUS HEMORRHAGE;

EID: 84857302077     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.660523     Document Type: Review

References (68)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291(15):1900-1. (Pubitemid 38509505)
2. Resnikoff S, Pascolini D, Etyaale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82(11):844-51. (Pubitemid 39573742)
3. Friedman DS, OColmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564-72. (Pubitemid 38456293)
4. Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. BMJ 2003;326(7387):485-8. (Pubitemid 36269633)
5. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007;29(9):1850-61. (Pubitemid 350214458)
6. Kaiser PK, Do DV. Ranibizumab for the treatment of neovascular AMD. Int J Clin Pract 2007;61(3):501-9.
7. Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 2007;125(9):1249-54. (Pubitemid 47403034)
8. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102(11):1640-2. (Pubitemid 15204559)
9. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115(1):116-26.
10. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122(4):598-614. (Pubitemid 38456297)
11. Funk M, Karl D, Georgopoulos M, et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116(12):2393-9.
12. Peer J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72(6):638-45.
13. Grunwald JE, Metelitsina TI, Dupont JC, et al. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005;46(3):1033-8. (Pubitemid 41321042)
14. Yoshida S, Yoshida A, Ishibashi T. Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation. Graefes Arch Clin Exp Ophthalmol 2004;242(5):409-13. (Pubitemid 38801529)
15. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37(9):1929-34. (Pubitemid 26324159)
16. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141(3):456-62. (Pubitemid 43265948)
17. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81(2):154-62. (Pubitemid 27092496)
18. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996;271(13):7788-95. (Pubitemid 26111064)
19. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006;90(12):1542-7. (Pubitemid 44862578)
20. Pauleikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina 2005;25(8):1065-84. (Pubitemid 44735105)
21. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112(6):1035-47. (Pubitemid 40797459)
22. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113(11):2002; e1,2002.12
23. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36(4):331-5. (Pubitemid 41073112)
24. Arevalo JF, Sanchez JG, Wu L, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the pan-American collaborative retina study. Ophthalmology 2010;117(10):1974; 81, 1981.e1
25. Bashshur ZF, Haddad ZA, Schakal AR, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009;148(1):59; 65.e1
26. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ 2010;340:c2459
27. Martin DF, Maguire MG, et al. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908.
28. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25(4):581-611. (Pubitemid 39099316)
29. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12(1):9-22. (Pubitemid 47001784)
30. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18(23):2893-904. (Pubitemid 39602308)
31. Yuan A, Kaiser PK. Emerging therapies for the treatment of neovascular age related macular degeneration. Semin Ophthalmol 2011;26(3):149-55.
32. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
33. Bayer and regeneron report positive top-line results of two phase 3 studies with VEGF trap-eye in wet age-related macular degeneration ; 22 November Available from http://investor. regeneron.com/releasedetail.cfm? ReleaseID=532099 Accessed 14 January 2010
34. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120(3):338-46. (Pubitemid 34250056)
35. Jackson TL, Antcliff RJ, Hillenkamp J, et al. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 2003;44(5):2141-6. (Pubitemid 36520310)
36. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46(2):726-33. (Pubitemid 40270359)
37. Blick SK, Keating GM, Wagstaff AJ. Ranibizumab. Drugs 2007;67(8):1199-206; discussion 1207-9
38. Lucentis (Ranibizumab Injection) Package Insert. Genentech; South San Francisco, CA: 2010
39. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011;31(9):1877-84.
40. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112(6):1048-53. (Pubitemid 40797460)
41. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93(11):2645-68. (Pubitemid 39506617)
42. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of bence jones proteins and immunoglobulin fragments. J Exp Med 1967;126(2):207-21.
43. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113(4):623; e1
44. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113(4):633; e1,633.e4
45. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31. (Pubitemid 44511557)
46. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432- 44. (Pubitemid 44511558)
47. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57; 65.e5
48. Sadda SR, Stoller G, Boyer DS, et al. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina 2010;30(9):1390-9
49. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145(2):239-48
50. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150(3):315; 324.e1
51. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration the EXCITE study. Ophthalmology 2011;118(5):831-9
52. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116(9):1731-9
53. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143(4):566-83
54. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009;148(1):43; 58.e1
55. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94(1):2-13
56. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144(4):627-37
57. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29(10):1424-31
58. 12-month results from DENALI study evaluating verteporforin PDT (visudyne-) combination therapy; 15 June 2010. Available from: http://www.qltinc.com/newsCenter/2010/100615.htm Accessed 14 January 2012
59. QLT annouces 12-month results from Novartis sponsored MONT BLANC study; 15 June 2009. Available from: http://www.qltinc.com/newsCenter/2009/090615.htm Accessed 14 January 2012
60. Lai T. Verteporfin PDT and Ranibizumab combination therapy for symptomatic macular polypoidal choroidal vasculopathy: EVEREST Result. Invest Ophthalmol Vis Sci 2010;51:E-abstract 2228
61. QLT announces final results from its RADICAL study evaluating verteporfin PDT (visudyne-) combination therapy in exudative AMD; 22 June 2010. Available from: http://www.qltinc.com/newsCenter/2010/100622.htm Accessed 14 January 2012
62. Bakri SJ, McCannel CA, Edwards AO, et al. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246(7):955-8
63. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2011 [Epub ahead of print]
64. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011;31(6):1028-35
65. Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95(8):1111-14
66. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007;27(5):541-51 (Pubitemid 46905143)
67. Chiang A, Chang LK, Yu F, et al. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 2008;28(9):1265-9
68. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128(10):1273-9